Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,725

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis

Open access
·2010·Journal of Hepatology
DOI 10.1016/j.jhep.2010.05.004
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2010.05.004

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 220

  1. Ginès, 1987, Compensated cirrhosis: natural history and prognostic factors, Hepatology, 7, 122, 10.1002/hep.1840070124 · DOI · Paper page
  2. Ripoll, 2007, Hepatic venous gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053/j.gastro.2007.05.024 · DOI · Paper page
  3. Schrier, 1988, Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis, Hepatology, 8, 1151, 10.1002/hep.1840080532 · DOI · Paper page
  4. Tandon, 2008, Bacterial infections, sepsis, and multiorgan failure in cirrhosis, Semin Liver Dis, 28, 26, 10.1055/s-2008-1040319 · DOI · Paper page
  5. Runyon, 2004, Management of adult patients with ascites due to cirrhosis, Hepatology, 39, 841, 10.1002/hep.20066 · DOI
  6. Runyon, 1992, The serum–ascites albumin gradient is superior to the exudate–transudate concept in the differential diagnosis of ascites, Ann Intern Med, 117, 215, 10.7326/0003-4819-117-3-215 · DOI
  7. Rimola, 2000, Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club, J Hepatol, 32, 142, 10.1016/S0168-8278(00)80201-9 · DOI · Paper page
  8. Moore, 2003, The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club, Hepatology, 38, 258, 10.1053/jhep.2003.50315 · DOI · Paper page
  9. Llach, 1988, Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites, Gastroenterology, 94, 482, 10.1016/0016-5085(88)90441-6 · DOI
  10. Caregaro, 1994, Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis, Arch Intern Med, 154, 201, 10.1001/archinte.1994.00420020117013 · DOI · Paper page
  11. Heuman, 2004, Persistent ascites and low sodium identify patients with cirrhosis and low MELD score who are at high risk for early death, Hepatology, 40, 802, 10.1002/hep.1840400409 · DOI
  12. Ring-Larsen, 1986, Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture, Br Med J, 292, 1351, 10.1136/bmj.292.6532.1351 · DOI
  13. Gatta, 1991, A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped-care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients with ascites, Hepatology, 14, 231, 10.1002/hep.1840140205 · DOI
  14. Bernardi, 1993, Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content, Liver, 13, 156, 10.1111/j.1600-0676.1993.tb00624.x · DOI
  15. Gauthier, 1986, Salt or not salt in the treatment of cirrhotic ascites: a randomized study, Gut, 27, 705, 10.1136/gut.27.6.705 · DOI
  16. Angeli, 1990, Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance, Eur J Clin Invest, 20, 111, 10.1111/j.1365-2362.1990.tb01800.x · DOI
  17. Angeli, 1992, Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention, Hepatology, 15, 651, 10.1002/hep.1840150416 · DOI
  18. Bernardi, 1985, Importance of plasma aldosterone concentration on natriuretic effect of spironolactone in patients with liver cirrhosis and ascites, Digestion, 31, 189, 10.1159/000199198 · DOI
  19. Pérez-Ayuso, 1984, Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites, Gastroenterology, 84, 961, 10.1016/0016-5085(83)90198-1 · DOI
  20. Angeli, 1994, Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites, Hepatology, 19, 72, 10.1002/hep.1840190113 · DOI
  21. Angeli, 2010, Combined versus sequential diuretic treatment of ascites in nonazotemic patients with cirrhosis: results of an open randomized clinical trial, Gut, 59, 98, 10.1136/gut.2008.176495 · DOI
  22. Santos, 2003, Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety, J Hepatol, 39, 187, 10.1016/S0168-8278(03)00188-0 · DOI
  23. Bernardi, 2010, Optimum use of diuretics in managing ascites in patients with cirrhosis, Gut, 59, 10, 10.1136/gut.2009.189506 · DOI
  24. Shear, 1970, Compartimentalization of ascites and edema in patients with cirrhosis, N Engl J Med, 282, 1391, 10.1056/NEJM197006182822502 · DOI
  25. Marchesini, 2001, Factors associated with poor health-related quality of life of patients with cirrhosis, Gastroenterology, 120, 170, 10.1053/gast.2001.21193 · DOI · Paper page
  26. Angeli, 1996, Cirrhosis and muscle cramps: evidence of a causal relationship, Hepatology, 23, 264, 10.1002/hep.510230211 · DOI
  27. Ginès, 1987, Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study, Gastroenterology, 92, 234, 10.1016/0016-5085(87)91007-9 · DOI · Paper page
  28. Ginès, 1988, Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis, Gastroenterology, 94, 1493, 10.1016/0016-5085(88)90691-9 · DOI · Paper page
  29. Salerno, 1987, Repeated paracentesis and i.v. albumin infusion to treat “tense ascites” in cirrhotic patients: a safe alternative therapy, J Hepatol, 5, 102, 10.1016/S0168-8278(87)80067-3 · DOI
  30. Fassio, 1992, Paracentesis with dextran 70 vs. paracentesis with albumin in cirrhosis with tense ascites. Results of a randomized study, J Hepatol, 14, 310, 10.1016/0168-8278(92)90176-P · DOI
  31. Acharya, 1992, Large-volume paracentesis and intravenous dextran to treat tense ascites, J Clin Gastroentrol, 14, 31, 10.1097/00004836-199201000-00008 · DOI
  32. Solà, 1994, Total paracentesis with dextran 40 vs. diuretics in the treatment of ascites in cirrhosis: a randomized controlled study, J Hepatol, 20, 282, 10.1016/S0168-8278(05)80070-4 · DOI
  33. Ginès, 1996, Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis, Gastroenterology, 111, 1002, 10.1016/S0016-5085(96)70068-9 · DOI · Paper page
  34. Pache, 2005, Severe hemorrhage following abdominal paracentesis for ascites in patients with liver disease, Aliment Pharmacol Ther, 21, 525, 10.1111/j.1365-2036.2005.02387.x · DOI
  35. Pozzi, 1994, Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites, Gastroenterology, 106, 709, 10.1016/0016-5085(94)90706-4 · DOI
  36. Ruiz del Arbol, 1997, Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis, Gastroenterology, 113, 579, 10.1053/gast.1997.v113.pm9247479 · DOI · Paper page
  37. Sola-Vera, 2003, Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites, Hepatology, 37, 1147, 10.1053/jhep.2003.50169 · DOI
  38. Moreau, 2006, Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail, Liver Int, 26, 46, 10.1111/j.1478-3231.2005.01188.x · DOI
  39. Panos, 1990, Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size, Hepatology, 11, 662, 10.1002/hep.1840110420 · DOI
  40. Christidis, 2001, Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions, J Hepatol, 35, 726, 10.1016/S0168-8278(01)00200-8 · DOI
  41. Fernández-Esparrach, 1997, Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo, J Hepatol, 26, 614, 10.1016/S0168-8278(97)80427-8 · DOI
  42. Lin, 2005, Should bleeding tendency deter abdominal paracentesis?, Dig Liver Dis, 37, 946, 10.1016/j.dld.2005.07.009 · DOI
  43. Boyer, 1979, Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease, Gastroenterology, 77, 215, 10.1016/0016-5085(79)90268-3 · DOI
  44. Clària, 2005, Effects of celecoxib and naproxen on renal function in nonaziotemic patients with cirrhosis and ascites, Hepatology, 41, 579, 10.1002/hep.20595 · DOI
  45. Pariente, 1985, Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites, Gastroenterology, 88, 1255, 10.1016/S0016-5085(85)80088-3 · DOI
  46. Gentilini, 1993, Effects of low-dose captopril on renal haemodynamics and function in patients with cirrhosis of the liver, Gastroenterology, 104, 588, 10.1016/0016-5085(93)90431-B · DOI
  47. Albillos, 1995, Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function, Gastroenterology, 109, 1257, 10.1016/0016-5085(95)90586-3 · DOI
  48. Llach, 1993, Effect of dipyridamole on kidney function in cirrhosis, Hepatology, 17, 59
  49. Cabrera, 1982, Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage, Gastroenterology, 82, 97, 10.1016/0016-5085(82)90129-9 · DOI
  50. Haupel, 2001, Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis, Am J Gastroenterol, 96, 2206, 10.1111/j.1572-0241.2001.03958.x · DOI
  51. Guevara, 2004, Effects of contrast media on renal function in patients with cirrhosis: a prospective study, Hepatology, 40, 646, 10.1002/hep.20373 · DOI
  52. Arroyo, 1996, Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis, Hepatology, 23, 164, 10.1002/hep.510230122 · DOI · Paper page
  53. Salerno, 1993, Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 outpatients, Am J Gastroenterol, 88, 514
  54. Guardiola, 2002, External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites, Am J Gastroenterol, 97, 2374
  55. Moreau, 2004, Clinical characteristics and outcome of patients with cirrhosis and refractory ascites, Liver Int, 24, 457, 10.1111/j.1478-3231.2004.0991.x · DOI
  56. Kamath, 2001, A model to predict survival in patients with end-stage liver disease, Hepatology, 33, 464, 10.1053/jhep.2001.22172 · DOI · Paper page
  57. Durand, 2008, Assessment of prognosis in cirrhosis, Semin Liver Dis, 28, 110, 10.1055/s-2008-1040325 · DOI · Paper page
  58. Silberhumer, 2006, Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?, Transpl Int, 19, 275, 10.1111/j.1432-2277.2006.00250.x · DOI
  59. O’Leary, 2008, Indications for liver transplantation, Gastroenterology, 134, 1764, 10.1053/j.gastro.2008.02.028 · DOI
  60. Kim, 2008, Hyponatremia and mortality among patients on the liver transplant waiting list, N Engl J Med, 359, 1018, 10.1056/NEJMoa0801209 · DOI · Paper page
  61. Luca, 2007, An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis, Liver Transpl, 13, 1174, 10.1002/lt.21197 · DOI
  62. Moore, 2006, Guidelines on the management of ascites in cirrhosis, Gut, 55, vi1, 10.1136/gut.2006.099580 · DOI
  63. Boyer, 2005, The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension, Hepatology, 41, 386, 10.1002/hep.20559 · DOI
  64. Ochs, 1995, The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites, N Engl J Med, 332, 1192, 10.1056/NEJM199505043321803 · DOI · Paper page
  65. Wong, 1995, Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites, Ann Intern Med, 122, 816, 10.7326/0003-4819-122-11-199506010-00002 · DOI
  66. Sanyal, 1997, The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts, Gastroenterology, 112, 889, 10.1053/gast.1997.v112.pm9041251 · DOI · Paper page
  67. Quiroga, 1995, Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters, Hepatology, 21, 986
  68. Colombato, 1996, Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients, Gut, 39, 600, 10.1136/gut.39.4.600 · DOI
  69. Huonker, 1999, Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt, Gut, 44, 743, 10.1136/gut.44.5.743 · DOI
  70. Merli, 2002, Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS), Am J Gastroenterol, 97, 142, 10.1111/j.1572-0241.2002.05438.x · DOI
  71. Lotterer, 1999, Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis, Hepatology, 29, 632, 10.1002/hep.510290302 · DOI
  72. Wong, 1997, The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt, Gastroenterology, 112, 899, 10.1053/gast.1997.v112.pm9041252 · DOI
  73. Guevara, 1998, Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems, Hepatology, 28, 416, 10.1002/hep.510280219 · DOI · Paper page
  74. Gerbes, 1998, Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: comparison of patients with ascites, with refractory ascites, or without ascites, Hepatology, 28, 683, 10.1002/hep.510280313 · DOI
  75. Rössle, 2000, A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites, N Engl J Med, 342, 1701, 10.1056/NEJM200006083422303 · DOI
  76. Gülberg, 2002, Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts, Digestion, 66, 127, 10.1159/000065593 · DOI
  77. Plauth, 2004, Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism, J Hepatol, 40, 228, 10.1016/j.jhep.2003.10.011 · DOI
  78. Campbell, 2005, Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy, Hepatology, 42, 635, 10.1002/hep.20840 · DOI
  79. Gur, 2004, Hepatic hydrothorax: pathophysiology, diagnosis and treatment – review of the literature, Liver Int, 24, 281, 10.1111/j.1478-3231.2004.0936.x · DOI
  80. Gordon, 1997, The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt, Hepatology, 25, 1366, 10.1002/hep.510250611 · DOI
  81. Siegerstetter, 2001, Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients, Eur J Gastroenterol Hepatol, 13, 529, 10.1097/00042737-200105000-00011 · DOI
  82. Wilputte, 2007, The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients, Acta Gastroenterol Belg, 70, 6
  83. Riggio, 2008, Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts, Am J Gastroenterol, 103, 2738, 10.1111/j.1572-0241.2008.02102.x · DOI · Paper page
  84. Casado, 1998, Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings, Gastroenterology, 114, 1296, 10.1016/S0016-5085(98)70436-6 · DOI · Paper page
  85. Lebrec, 1996, Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial, J Hepatol, 25, 135, 10.1016/S0168-8278(96)80065-1 · DOI · Paper page
  86. Ginès, 2002, Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis, Gastroenterology, 123, 1839, 10.1053/gast.2002.37073 · DOI
  87. Sanyal, 2003, The North American study for the treatment of refractory ascites, Gastroenterology, 124, 634, 10.1053/gast.2003.50088 · DOI · Paper page
  88. Salerno, 2004, Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites, Hepatology, 40, 629, 10.1002/hep.20364 · DOI
  89. Albillos, 2005, A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites, J Hepatol, 43, 990, 10.1016/j.jhep.2005.06.005 · DOI
  90. Deltenre, 2005, Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis, Liver Int, 25, 349, 10.1111/j.1478-3231.2005.01095.x · DOI
  91. D’Amico, 2005, Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis, Gastroenterology, 129, 1282, 10.1053/j.gastro.2005.07.031 · DOI
  92. Saab, 2006, TIPS versus paracentesis for cirrhotic patients with refractory ascites, Cochrane Database Syst Rev, CD004889
  93. Salerno, 2007, Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data, Gastroenterology, 133, 825, 10.1053/j.gastro.2007.06.020 · DOI · Paper page
  94. Singh, 2008, Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study, Am J Gastroenterol, 103, 1399, 10.1111/j.1572-0241.2008.01787.x · DOI
  95. Angeli, 1998, Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites, Hepatology, 28, 937, 10.1002/hep.510280407 · DOI
  96. Krag, 2007, Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome, Hepatology, 46, 1863, 10.1002/hep.21901 · DOI
  97. Ginès, 2010, Clinical trial: short term effects of combination of satavaptan, a selective vasopressin V receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia – a randomized, double blind, placebo controlled study, Aliment Pharmacol Ther, 31, 834, 10.1111/j.1365-2036.2010.04236.x · DOI
  98. Wong, 2010, Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis, J Hepatol, 53, 283, 10.1016/j.jhep.2010.02.036 · DOI
  99. Wong, 2009, Effects of satavaptan, an oral vasopressin V2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long-term, placebo-controlled study, J Hepatol, 50, S42, 10.1016/S0168-8278(09)60104-5 · DOI
  100. Caly, 1993, A prospective study of bacterial infections in patients with cirrhosis, J Hepatol, 18, 353, 10.1016/S0168-8278(05)80280-6 · DOI · Paper page
  101. Fernández, 2002, Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis, Hepatology, 35, 140, 10.1053/jhep.2002.30082 · DOI · Paper page
  102. Wong, 2005, Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club, Gut, 54, 718, 10.1136/gut.2004.038679 · DOI
  103. Garcia-Tsao, 2001, Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis, Gastroenterology, 120, 726, 10.1053/gast.2001.22580 · DOI
  104. Nousbaum, 2007, Diagnostic accuracy of the Multistix 8 SG® reagent strip in diagnosis of spontaneous bacterial peritonitis, Hepatology, 45, 1275, 10.1002/hep.21588 · DOI
  105. Evans, 2003, Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites, Hepatology, 37, 897, 10.1053/jhep.2003.50119 · DOI · Paper page
  106. Plessier, 2003, Coagulation disorders in patients with cirrhosis and severe sepsis, Liver Int, 23, 440, 10.1111/j.1478-3231.2003.00870.x · DOI
  107. Guarner, 1997, Spontaneous bacterial peritonitis, Semin Liver Dis, 17, 203, 10.1055/s-2007-1007198 · DOI
  108. Angeloni, 2003, Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis, Am J Gastroenterol, 98, 1844, 10.1111/j.1572-0241.2003.07620.x · DOI
  109. Nguyen Khac, 2008, Review article: utility of reagent strips in diagnosis of infected ascites in cirrhotic patients, Aliment Pharmacol Ther, 28, 282, 10.1111/j.1365-2036.2008.03735.x · DOI
  110. Runyon, 1984, Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis, Hepatology, 4, 1209, 10.1002/hep.1840040619 · DOI
  111. Terg, 1992, Analysis of clinical course and prognosis of culture-positive spontaneous bacterial peritonitis and neutrocytic ascites. Evidence of the same disease, Dig Dis Sci, 37, 1499, 10.1007/BF01296493 · DOI
  112. Xiol, 1996, Spontaneous bacterial empyema in cirrhotic patients: a prospective study, Hepatology, 23, 719, 10.1002/hep.510230410 · DOI
  113. Felisart, 1985, Cefotaxime is more effective than is ampicillin–tobramycin in cirrhotics with severe infections, Hepatology, 5, 457, 10.1002/hep.1840050319 · DOI · Paper page
  114. Rimola, 1995, Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study, Hepatology, 21, 674, 10.1002/hep.1840210312 · DOI
  115. Sort, 1999, Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis, N Engl J Med, 341, 403, 10.1056/NEJM199908053410603 · DOI
  116. Ricart, 2000, Amoxicillin–clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients, J Hepatol, 32, 596, 10.1016/S0168-8278(00)80221-4 · DOI
  117. Terg, 2000, Oral ciprofloxacin after a short course of intravenous ciprofloxacin in the treatment of spontaneous bacterial peritonitis: results of a multicenter, randomized study, J Hepatol, 33, 564, 10.1016/S0168-8278(00)80008-2 · DOI
  118. Angeli, 2006, Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost, Aliment Pharmacol Ther, 23, 75, 10.1111/j.1365-2036.2006.02706.x · DOI
  119. Follo, 1994, Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis, Hepatology, 20, 1495, 10.1002/hep.1840200619 · DOI · Paper page
  120. Fasolato, 2007, Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features, Hepatology, 45, 223, 10.1002/hep.21443 · DOI · Paper page
  121. Navasa, 1998, Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality, Hepatology, 27, 1227, 10.1002/hep.510270507 · DOI · Paper page
  122. Sigal, 2007, Restricted use of albumin for spontaneous bacterial peritonitis, Gut, 56, 597, 10.1136/gut.2006.113050 · DOI
  123. Terg, 2009, Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study, Liver Int, 29, 415, 10.1111/j.1478-3231.2008.01877.x · DOI
  124. Fernández, 2005, A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis, Hepatology, 42, 627, 10.1002/hep.20829 · DOI
  125. Rimola, 1985, Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage, Hepatology, 5, 463, 10.1002/hep.1840050320 · DOI
  126. Bleichner, 1986, Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage, Br J Surg, 73, 724, 10.1002/bjs.1800730916 · DOI
  127. Soriano, 1992, Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage, Gastroenterology, 103, 1267, 10.1016/0016-5085(92)91514-5 · DOI · Paper page
  128. Blaise, 1994, Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage, Hepatology, 20, 34, 10.1002/hep.1840200107 · DOI
  129. Bernard, 1995, Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study, Gastroenterology, 108, 1828, 10.1016/0016-5085(95)90146-9 · DOI · Paper page
  130. Pauwels, 1996, Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with a high risk of infection, Hepatology, 24, 802
  131. Deschenes, 1999, Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis, Am J Gastroenterol, 94, 2193, 10.1016/S0002-9270(99)00349-4 · DOI
  132. Bernard, 1999, Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis, Hepatology, 29, 1655, 10.1002/hep.510290608 · DOI · Paper page
  133. Hsieh, 1998, The effect of ciprofloxacin in the prevention of bacterial infection in patients with cirrhosis after upper gastrointestinal bleeding, Am J Gastroenterol, 93, 962, 10.1111/j.1572-0241.1998.00288.x · DOI
  134. Hou, 2004, Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial, Hepatology, 39, 746, 10.1002/hep.20126 · DOI · Paper page
  135. Goulis, 1998, Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage, Hepatology, 27, 1207, 10.1002/hep.510270504 · DOI
  136. Vivas, 2001, Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding, Dig Dis Sci, 46, 2752, 10.1023/A:1012739815892 · DOI
  137. Soares-Weiser, 2002, Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding, Cochrane Database Syst Rev, CD002907
  138. Carbonell, 2004, Improved survival after variceal bleeding in patients with cirrhosis over the past two decades, Hepatology, 40, 652, 10.1002/hep.20339 · DOI · Paper page
  139. Dupeyron, 1994, Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis, Antimicrob Agents Chemother, 38, 340, 10.1128/AAC.38.2.340 · DOI
  140. Aparicio, 1999, Development of quinolone-resistant strains of Escherichia coli in stools of patients with cirrhosis undergoing norfloxacin prophylaxis: clinical consequences, J Hepatol, 31, 277, 10.1016/S0168-8278(99)80225-6 · DOI
  141. Fernández, 2006, Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage, Gastroenterology, 131, 1049, 10.1053/j.gastro.2006.07.010 · DOI · Paper page
  142. Runyon, 1986, Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis, Gastroenterology, 91, 1343, 10.1016/0016-5085(86)90185-X · DOI · Paper page
  143. Andreu, 1993, Risk factors for spontaneous bacterial peritonitis, Gastroenterology, 104, 1133, 10.1016/0016-5085(93)90284-J · DOI · Paper page
  144. Llach, 1992, Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: relevance of ascitic fluid protein concentration, Hepatology, 16, 724, 10.1002/hep.1840160318 · DOI
  145. Guarner, 1999, Risk of a first community-acquired spontaneous bacterial peritonitis in cirrhotics with low ascitic fluid protein levels, Gastroenterology, 117, 414, 10.1053/gast.1999.0029900414 · DOI
  146. Soriano, 1991, Selective intestinal decontamination prevents spontaneous bacterial peritonitis, Gastroenterology, 100, 477, 10.1016/0016-5085(91)90219-B · DOI · Paper page
  147. Novella, 1997, Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin, Hepatology, 25, 532, 10.1002/hep.510250306 · DOI
  148. Grange, 1998, Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial, J Hepatol, 29, 430, 10.1016/S0168-8278(98)80061-5 · DOI
  149. Terg, 2008, Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study, J Hepatol, 48, 774, 10.1016/j.jhep.2008.01.024 · DOI
  150. Ginès, 1990, Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial, Hepatology, 12, 716, 10.1002/hep.1840120416 · DOI · Paper page
  151. Bauer, 2002, Daily norfloxacin is more effective than weekly rufloxacin in prevention of spontaneous bacterial peritonitis recurrence, Dig Dis Sci, 47, 1356, 10.1023/A:1015386901343 · DOI
  152. Rolachon, 1995, Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial, Hepatology, 22, 1171
  153. Singh, 1995, Trimethoprim–sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial, Ann Intern Med, 122, 595, 10.7326/0003-4819-122-8-199504150-00007 · DOI
  154. Campillo, 1998, Epidemiology of severe hospital acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin, Clin Infect Dis, 26, 1066, 10.1086/520273 · DOI
  155. Ginès, 1998, Hyponatremia in cirrhosis: from pathogenesis to treatment, Hepatology, 28, 851, 10.1002/hep.510280337 · DOI
  156. Arroyo, 1986, Antidiuretic hormone and the pathogenesis of water retention in cirrhosis with ascites, Semin Liver Dis, 6, 353, 10.1055/s-2008-1040617 · DOI
  157. Ginès P, Cárdenas A, Schrier RW. Liver disease and the kidney. In: Schrier Robert W, editor. Diseases of the kidney & urinary tract. 8th ed., vol. III. Lippincott Williams & Wilkins; p. 2179–2205.
  158. Angeli, 2006, Hyponatremia in cirrhosis: results of a patient population survey, Hepatology, 44, 1535, 10.1002/hep.21412 · DOI · Paper page
  159. 2007, Expert panel recommendations, Am J Med, 120, S1, 10.1016/j.amjmed.2007.09.001 · DOI · Paper page
  160. Arroyo, 1976, Prognostic value of spontaneous hyponatremia in cirrhosis with ascites, Am J Dig Dis, 21, 249, 10.1007/BF01095898 · DOI
  161. Cosby, 1989, New classification with prognostic value in cirrhotic patients, Miner Electrolyte Metab, 15, 261
  162. Porcel, 2002, Dilutional hyponatremia in patients with cirrhosis and ascites, Arch Intern Med, 162, 323, 10.1001/archinte.162.3.323 · DOI
  163. Biggins, 2005, Serum sodium predicts mortality in patients listed for liver transplantation, Hepatology, 41, 32, 10.1002/hep.20517 · DOI · Paper page
  164. Ruf, 2005, Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone, Liver Transpl, 11, 336, 10.1002/lt.20329 · DOI · Paper page
  165. Biggins, 2006, Evidence-based incorporation of serum sodium concentration into MELD, Gastroenterology, 130, 1652, 10.1053/j.gastro.2006.02.010 · DOI
  166. Londoño, 2007, MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation, Gut, 56, 1283, 10.1136/gut.2006.102764 · DOI
  167. Londoño, 2006, Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation, Gastroenterology, 130, 1135, 10.1053/j.gastro.2006.02.017 · DOI
  168. Dawas, 2007, The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study, Liver Transpl, 13, 1115, 10.1002/lt.21154 · DOI
  169. Yun, 2009, Impact of pretransplant hyponatremia on outcome following liver transplantation, Hepatology, 49, 1610, 10.1002/hep.22846 · DOI
  170. McCormick, 1990, Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites, Gut, 31, 204, 10.1136/gut.31.2.204 · DOI
  171. Jalan, 2007, Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trail, J Hepatol, 46, 232A, 10.1016/S0168-8278(07)61830-3 · DOI
  172. Troyer, 1976, Demeclocycline treatment of water retention in cirrhosis, Ann Intern Med, 85, 336, 10.7326/0003-4819-85-3-336 · DOI
  173. Pérez-Ayuso, 1984, Effect of demeclocycline on renal function and urinary prostaglandin E2 and kallikrein in hyponatremic cirrhotics, Nephron, 36, 30, 10.1159/000183112 · DOI
  174. Carrilho, 1977, Renal failure associated with demeclocycline in cirrhosis, Ann Intern Med, 87, 195, 10.7326/0003-4819-87-2-195 · DOI
  175. Gadano, 2000, Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis, J Hepatol, 32, 38, 10.1016/S0168-8278(00)80187-7 · DOI
  176. Quittnat, 2006, Vaptans and the treatment of water-retaining disorders, Semin Nephrol, 26, 234, 10.1016/j.semnephrol.2006.02.003 · DOI
  177. Ginès, 2007, The vaptans: a promising therapy in the management of advanced cirrhosis, J Hepatol, 46, 1150, 10.1016/j.jhep.2007.03.007 · DOI
  178. Decaux, 2008, Non-peptide arginine–vasopressin antagonists: the vaptans, Lancet, 371, 1624, 10.1016/S0140-6736(08)60695-9 · DOI · Paper page
  179. Afdhal, 2005, Randomized, placebo-controlled trial of tolvaptan, a novel V2-receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis, Hepatology, 42, LB19A
  180. O’Leary, 2009, Conivaptan increases serum sodium in hyponatremic patients with end stage liver disease, Liver Transpl, 15, 1325, 10.1002/lt.21836 · DOI
  181. Gerbes, 2003, Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial, Gastroenterology, 124, 933, 10.1053/gast.2003.50143 · DOI · Paper page
  182. Wong, 2003, A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial, Hepatology, 37, 182, 10.1053/jhep.2003.50021 · DOI · Paper page
  183. Salerno, 2007, Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis, Gut, 56, 1310
  184. Bellomo, 2004, Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group, Crit Care, 8, R204, 10.1186/cc2872 · DOI
  185. Stadlbauer, 2008, Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis, Gastroenterology, 134, 111, 10.1053/j.gastro.2007.10.055 · DOI
  186. Ginès, 2009, Renal failure in cirrhosis, N Engl J Med, 361, 1279, 10.1056/NEJMra0809139 · DOI · Paper page
  187. Dagher, 2001, The hepatorenal syndrome, Gut, 19, 729, 10.1136/gut.49.5.729 · DOI
  188. Thabut, 2007, Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure, Hepatology, 46, 1872, 10.1002/hep.21920 · DOI · Paper page
  189. Terra, 2005, Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score, Gastroenterology, 129, 1944, 10.1053/j.gastro.2005.09.024 · DOI
  190. Ginès, 1993, Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites, Gastroenterology, 105, 229, 10.1016/0016-5085(93)90031-7 · DOI · Paper page
  191. Alessandria, 2005, MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation, Hepatology, 41, 1282, 10.1002/hep.20687 · DOI · Paper page
  192. Kew, 1972, The effect of octapressin on renal and intrarenal blood flow in cirrhosis of the liver, Gut, 13, 293, 10.1136/gut.13.4.293 · DOI
  193. Lenz, 1991, Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor, Gastroenterology, 101, 1060, 10.1016/0016-5085(91)90734-3 · DOI
  194. Guevara, 1998, Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion, Hepatology, 27, 35, 10.1002/hep.510270107 · DOI
  195. Gülberg, 1999, Long term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine, Hepatology, 30, 870, 10.1002/hep.510300430 · DOI
  196. Moreau, 2002, Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study, Gastroenterology, 122, 923, 10.1053/gast.2002.32364 · DOI
  197. Fabrizi, 2006, Metaanalysis: terlipressin therapy for hepatorenal syndrome, Aliment Pharmacol Ther, 24, 935, 10.1111/j.1365-2036.2006.03086.x · DOI
  198. Gluud, 2006, Terlipressin for hepatorenal syndrome, Cochrane Database Syst Rev, 4, CD005162
  199. Sanyal, 2008, A randomized prospective double blind, placebo controlled study of terlipressin for type 1 hepatorenal syndrome, Gastroenterology, 134, 1360, 10.1053/j.gastro.2008.02.014 · DOI · Paper page
  200. Martin, 2008, Terlipressin and albúmina vs albúmina in patients with cirrhosis and hepatorenal syndrome: a randomized study, Gastroenterology, 134, 1352, 10.1053/j.gastro.2008.02.024 · DOI · Paper page

200 of 220 shown

Cited by

See all 1,725

Metadata

Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2010-09
Volume
53
Issue
3
Pages
397-417
ISSN
0168-8278 (ISSN-L)
DOI
10.1016/j.jhep.2010.05.004
OpenAlex
W1228830179
Cited by
1,725
References
6
FWCI
48.73
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. https://app.cochat.ai/papers/10.1016/j.jhep.2010.05.004
The paper
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. (2010). Journal of Hepatology. https://doi.org/10.1016/j.jhep.2010.05.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.